Sanofi

Cursor Launches EMEA Office and Expands Team

Cursor, a multi-model AI coding platform, announced the establishment of dedicated teams for the EMEA region and plans to open a London headquarters in summer 2026. The company said EMEA revenue has tripled quarter-over-quarter this year and expects to grow its EMEA headcount to approximately 200 employees by year-end, hiring across go-to-market, engineering, customer success and operations. Cursor named enterprise customers in the region, including British Airways, BP, Deliveroo, Nokia and Sanofi, and said it will invest in region-specific capabilities to address data locality, privacy and regulatory compliance for highly regulated industries. Executives from Cursor and partner customers (Nokia, Accenture) are quoted on productivity and strategic benefits. The announcement frames the expansion as a long-term commercial and support commitment to accelerate enterprise AI adoption in Europe.

6-K Financial Filing Analysis for Sanofi

AI Analysis of 6-K for period 2026-05-27.

Anthropic Acquires Coefficient Bio for $400M

Anthropic acquired Coefficient Bio — a roughly eight-month-old startup with fewer than ten employees — for $400 million in stock. Coefficient Bio was founded by Samuel Stanton and Nathan C. Frey, both ex-Genentech computational biology researchers, and had no public product or disclosed revenue. Anthropic intends to fold the team into its Health Care & Life Sciences division (led by Eric Kauderer-Abrams) to accelerate Claude's capabilities in protein design, biomolecule modelling and other biological foundation-model work. The deal follows Anthropic product launches including Claude for Life Sciences (Oct 2025) and Claude for Healthcare (Jan 2026) and sits alongside prior Anthropic acquisitions (Bun, Vercept). Anthropic closed a $30 billion Series G in Feb 2026 valuing the company at ~$380 billion post-money; the Coefficient deal represents a small dilution (~0.1%) at that scale. The acquisition is positioned as a talent- and domain-expertise buy to deepen Claude's role across R&D and drug-discovery workflows.